Search

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cytotoxicity may involve inhibition of peroxisome proliferator-activated receptor alpha. Fenofibrate activates peroxisome proliferator-activated receptor alpha and inhibits SARS-CoV-2 replication in vitro. Whether fenofibrate can be used to treat coronavirus disease 2019 (COVID-19) infection in humans remains unknown. Here, we randomly assigned inpatients and outpatients with COVID-19 within 14 d of symptom onset to 145 mg of oral fenofibrate nanocrystal formulation versus placebo for 10 d, in a double-blinded fashion. The primary endpoint was a severity score whereby participants were ranked across hierarchical tiers incorporating time to death, mechanical ventilation duration, oxygenation, hospitalization and symptom severity and duration. In total, 701 participants were randomized to fenofibrate (n = 351) or placebo (n = 350). The mean age of participants was 49 ± 16 years, 330 (47%) were female, mean body mass index was 28 ± 6 kg/m

We present a rare association between Sweet Syndrome and Gastric Cancer in 72 year old woman, who came to the hospital with a painful skin lesion, bone pain and polyarthralgia. Initially the skin lesion was studied and it showed Neutrophilic Dermatitis/Paniculitis. An Abdominal CT Scan showed Retroperitoneal limphadenopathy, 2 weeks after admission developed Acute Emetic Syndrome, that did not improve with standard therapy, an upper endoscopy was done showing Gastric Ulcer and Duodenal Infiltrative Lesion, pathologic study showed Gastric Adenocarcinoma that went Lymphathic and Liver metastases. This is the fourth case with this association reported in international bibliography. ( Rev Med Hered 2001; 12: 139-141 ).